The quality of information on monitoring for haematological adverse drug reactions

British Journal of Clinical Pharmacology

Volumn 60, Issue 4, 2005, Pages 448-451

  Ferner, R E ^a   Coleman, Jamie ^a   Pirmohamed, Munir ^b   Constable, Simon A ^b   Rouse, Andrew ^c  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Heart of Birmingham Teaching Primary Care Trust   (United Kingdom)

Author keywords

Drug therapy; Haematological diseases; Medicines regulation; Monitoring; Prevention and control

Indexed keywords

ADVERSE DRUG REACTION; ARTICLE; AUSTRALIA; DRUG INDUSTRY; DRUG INFORMATION; DRUG MONITORING; HEMATOLOGIC DISEASE; PRIORITY JOURNAL; RATING SCALE; UNITED KINGDOM; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG MONITORING; GREAT BRITAIN; HEMATOLOGIC DISEASES; HUMANS; PRESCRIPTIONS, DRUG;

EID: 26444585526     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02440.x     Document Type: Article

References (5)

1. Pirmohamed M, Ferner RE. Monitoring drug treatment. BMJ 2003; 327: 1179-81.
2. Editorial. Chloramphenicol toxicity. Lancet 1969; ii: 476.
3. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327: 1222-5.
4. Association of British Pharmaceutical Industry. Electronic Medicines Compendium. Datapharm Communications Ltd. 2003. http:// emc.medicines.org.uk/ (Last accessed 27th December 2004).
5. Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47: 52-6.